Universität zu Köln

Eichenauer, Dennis A. and Engert, Andreas (2017). The evolving role of targeted drugs in the treatment of Hodgkin lymphoma. Expert Rev. Hematol., 10 (9). S. 775 - 783. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1747-4094

Full text not available from this repository.

Abstract

Introduction: Hodgkin lymphoma (HL) is a B-cell-derived malignancy mostly affecting young adults. More than 80% of patients are cured after stage-adapted first-line treatment with chemotherapy and/or radiotherapy. About 50% of patients with disease recurrence achieve long-term remission with second-line treatment consisting of high-dose chemotherapy and autologous stem cell transplantation. However, HL treatment is often associated with acute toxicity and in part life-threatening late effects. Implementing targeted drugs may reduce toxicity and potentially further optimize efficacy. In recent years, the CD30-directed antibody-drug conjugate brentuximab vedotin (BV) and anti-PD-1 antibodies, nivolumab and pembrolizumab, underwent extensive evaluation in HL. They have exhibited encouraging single agent activity and a favorable toxicity profile in patients with multiple relapses. Therefore, they are currently under investigation in different additional indications.Areas covered: This article gives an overview over clinical trials evaluating targeted drugs either as single agent or as part of combination therapies in HL patients.Expert commentary: A multitude of targeted drugs are investigated in HL. Promising data have particularly emerged from studies with BV and anti-PD-1 antibodies. However, mature data needed for final conclusions are still pending.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Eichenauer, Dennis A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-245307
DOI:	10.1080/17474086.2017.1350167
Journal or Publication Title:	Expert Rev. Hematol.
Volume:	10
Number:	9
Page Range:	S. 775 - 783
Date:	2017
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1747-4094
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; CLINICAL-PRACTICE GUIDELINES; PHASE-II TRIAL; BRENTUXIMAB VEDOTIN; OPEN-LABEL; PD-1 BLOCKADE; EARLY-STAGE; SINGLE-ARM; RITUXIMAB; THERAPY Multiple languages Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24530